🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💬 .Scott Tagawa of Weill Cornell Medicine speaks about the #VIOLETStudy, a single-center, single-arm, phase I/II first-in-human results of terbium-161Tb-PSMA-I&T radioligand treatment in patients with #mCRPC. 📺 Watch Dr. Tagawa's interview from #ASCO25 here: buff.ly/3wZlKIL

“The majority of #BladderCancers are superficial lesions inside the lining of the bladder that show up as little discolorations, plaques, or nodules. #Cystoscopy is an absolute must because it also then enables you to sample the urine and perform cytology." 💭 Dr.

➡️ Dr. jc discusses the significance of seeing positive outcomes with #zanzalintinib plus #nivolumab in a first-line setting for treating patients with untreated #ccRCC. 💬 Watch the full interview with Dr. Chahoud here: buff.ly/k1heFJE

🔬 Researchers found evidence that the use of #ctDNA testing in monitoring treatment in patients with primary #UrethralCancer and #PenileSquamousCellCarcinoma can reliably and accurately monitor treatment. ➡️ Learn more about the study's results here: buff.ly/5ZYillm

❗Noting the ongoing worldwide shortage of #BCG, Dr. Dickon Hayne, an SAC member of ANZUP, comments on his study’s results that investigated the safety and efficacy of including #mitomycin with BCG for the treatment of high-risk #NMIBC. ▶️ Watch Dr. Hayne's interview

⚕️ Brenda Martone discusses the burden that treatment costs and travel can have on patients with cancer in a new clip from our roundtable focused on the challenges of patient-centered care: buff.ly/09Nhw4s 🔎 The panel featured experts Christopher Wallis (he/him/his), Vadim Koshkin MD,

❗️ A recent study has shown that intravesical #gemcitabine and #docetaxel may be an alternative therapy that patients with high-grade #NMIBC can tolerate better, compared with BCG re-induction after failure of initial induction: buff.ly/Y4PYSzq

📺 In a clip from our new roundtable series, Jacqueline T. Brown, MD discusses financial barriers that patients may face when being prescribed treatments: buff.ly/HhMGPO8 ⚕️ The panel focuses on the challenges of patient-centered care, and features experts Christopher Wallis (he/him/his),

📺 Zeynep Irem Ozay, MD of Huntsman Cancer Institute discusses her study that compared the efficacy of #cabazitaxel with lutetium Lu-177 vipivotide tetraxetan in patients with metastatic #CRPC: buff.ly/7iZKeXP 👉 Real-world results pointed to the higher efficacy of lutetium over

🔬 While the #FASTRACK II trial determined that the safety and efficacy of SABR was superior as a nonsurgical definitive therapy option, an evaluation of the trial has investigated whether SABR is more cost-effective for patients with inoperable #RCC compared with the use of

📺 A new interview with Dr. Axel Bex of Royal Free London focuses on the phase II #NEOAVAX trial, which investigated avelumab/axitinib as a neoadjuvant therapy in patients with high-risk #RCC: buff.ly/JNYLEMr 👉 Professor Bex breaks down the rationale for combining avelumab

📺 In the first of a three-part series, Jordan Ciuro, MD spoke with Umang Swami on the ongoing efforts to understand and reduce disparities in the real-world application of intensified therapy for #mHSPC: buff.ly/OUgoJo5 🔎 They explore future research directions,

⭐ Get a comprehensive overview of emerging radiopharmaceutical trials in #prostatecancer in our new video featuring Dr. Robert Flavell of UC San Francisco: buff.ly/ePVRB5I 🔎 He highlights the rapid expansion of lutetium PSMA therapies into earlier disease settings, including

📺 In our latest video series, Drs. Vignesh Packiam, MD and Nitin Yerram M.D. explore the latest advances in #NMIBC, including combination #immunotherapy with BCG: buff.ly/D11fEFh 👉 In part 1 of the series, they provide a foundational overview of NMIBC, highlighting how BCG has

📺 We spoke with Nadine Mallak, MD of OHSU Radiology on an ongoing study that is evaluating the use of 18F-fluciclovine PET/CT to detect metastatic disease in patients with biochemical recurrence of #prostatecancer when PSMA PET/CT is negative: buff.ly/GYeKzix 👉 Watch to

⚙️ A new evaluation of several trials has shed light on the prognostic performance of the 15G score in patients with metastatic #ccRCC. 📉 Learn which treatments - including #sunitinib and #atezolizumab - were linked to worse PFS rates: guoncologynow.com/post/15-gene-p…

💊In #urothelial carcinoma, the basal/squamous molecular subtype and the presence of certain DDR gene alterations are linked to enhanced benefit of cisplatin-based chemotherapy. ❗️However, A recent study found that the relationship between these biomarkers did not correlate with

⭐ In our new video series, Drs. Shahid Ahmed and Jordan Ciuro, MD, both of Winship Cancer Institute of Emory University, discuss the evolving role of #PSMA PET imaging, treatment intensification, and de-escalation strategies in metastatic and localized #prostatecancer: buff.ly/eVjaj3f

📺 A regional roundtable discussion, moderated by Dr. Scott Sellinger of Advanced Urology Institute, focused on the evolving treatment landscape of advanced #prostatecancer, including the use of triplet therapy in the castration-sensitive setting, and more:

📺 In our recent video series, Drs. Vignesh Packiam, MD of Rutgers Cancer Institute and Nitin Yerram M.D. of HackensackUMC Department of Urology explore the latest advances in #NMIBC, including combination #immunotherapy with BCG: buff.ly/Q3kTagh 👉 In the final part of the series, they conclude with the